View Future GrowthAlterity Therapeutics 過去の業績過去 基準チェック /06Alterity Therapeuticsの収益は年間平均-1.5%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間30% 10.3%割合で 増加しています。主要情報-1.51%収益成長率29.77%EPS成長率Biotechs 業界の成長17.04%収益成長率10.26%株主資本利益率-26.89%ネット・マージン-219.85%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesAlterity Therapeutics Receives Positive FDA Feedback on Ath434 Phase 3 Program in Multiple System AtrophyApr 29Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of NeurologyApr 24Alterity Therapeutics Limited Appoints Ann Cunningham as Independent Non-Executive Director, Effective April 17, 2026Apr 17Alterity Therapeutics Limited Receives Positive FDA Feedback on Ath434 Phase 3 ProgramMar 30Alterity Therapeutics Limited Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, Effective March 2026Mar 05Alterity Therapeutics Limited Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying TreatmentsMar 03Alterity Therapeutics Presents Promising Impact of Ath434 on Orthostatic Hypotension and Disease Progression in Msa At the 36Th International Symposium on the Autonomic Nervous SystemNov 11Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial At the 2025 International Congress of Parkinson's Disease and Movement DisordersOct 10Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement DisordersOct 03Alterity Therapeutics Limited, Annual General Meeting, Nov 21, 2025Sep 24Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.Sep 08Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System AtrophyJul 29Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the BioMUSE Natural History StudyJul 24Alterity Therapeutics Limited Prominently Featured at the International MSA CongressMay 12Alterity Therapeutics Grants U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System AtrophyMay 06Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA SymposiumApr 28Alterity Therapeutics Presents Encouraging New Data from Its Ath434 Phase 2 Trial in Multiple System Atrophy At the American Academy of Neurology Annual MeetingApr 10Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.Apr 07Alterity Therapeutics Limited Completes Last Patient Visit in Open-Label TrialMar 27Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 40.7 million.Feb 11Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.118724 million.Feb 04Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical EfficacyJan 30Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System AtrophyDec 04Alterity Therapeutics Limited Announces Management ChangesNov 20Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International SymposiumNov 12Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434Nov 06Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024Oct 23Alterity Therapeutics Limited Announces Chief Financial Officer ChangesSep 30Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.Jul 20+ 1 more updateAlterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyJul 17Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewMay 09Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative DiseasesApr 30Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.Feb 16Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewFeb 06Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.Jan 08Alterity Therapeutics Limited Announces CFO ChangesDec 21Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's DiseaseDec 04Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNov 29Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Nov 23+ 1 more updateAlterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System AtrophyNov 10Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023Oct 31Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer'sAug 24Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 StudyJul 27Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian DisorderMay 31Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System AtrophyMay 11Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and AustriaFeb 16Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's DiseaseJan 31Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System AtrophyJan 25Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System AtrophyJan 09Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK Aug 25Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy Jul 06Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology Sep 16収支内訳Alterity Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:ATHE 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 257-1571730 Sep 256-1361530 Jun 255-1251431 Mar 255-1661631 Dec 244-2061830 Sep 244-1951830 Jun 244-1951931 Mar 244-1651531 Dec 233-1241230 Sep 234-1351230 Jun 234-1451331 Mar 235-1451431 Dec 225-1451630 Sep 225-1451530 Jun 225-1361531 Mar 225-1351431 Dec 215-1371330 Sep 215-1481330 Jun 214-1571231 Mar 212-1671131 Dec 200-1651030 Sep 200-1541030 Jun 200-1331031 Mar 202-1341131 Dec 194-1341330 Sep 195-1241330 Jun 195-1241331 Mar 195-1141231 Dec 184-1041030 Sep 184-94830 Jun 183-84731 Mar 183-84531 Dec 173-84430 Sep 173-84530 Jun 173-84631 Mar 174-84731 Dec 164-94830 Sep 164-84930 Jun 165-841031 Mar 165-841131 Dec 156-751230 Sep 156-751230 Jun 156-6512質の高い収益: ATHEは現在利益が出ていません。利益率の向上: ATHEは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ATHEは利益が出ておらず、過去 5 年間で損失は年間1.5%の割合で増加しています。成長の加速: ATHEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ATHEは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: ATHEは現在利益が出ていないため、自己資本利益率 ( -26.89% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 11:10終値2026/05/01 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alterity Therapeutics Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関George ZavoicoB. Riley Securities, Inc.Madeleine WilliamsCanaccord GenuityAydin HuseynovLadenburg Thalmann & Company3 その他のアナリストを表示
Alterity Therapeutics Receives Positive FDA Feedback on Ath434 Phase 3 Program in Multiple System AtrophyApr 29
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of NeurologyApr 24
Alterity Therapeutics Limited Appoints Ann Cunningham as Independent Non-Executive Director, Effective April 17, 2026Apr 17
Alterity Therapeutics Limited Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, Effective March 2026Mar 05
Alterity Therapeutics Limited Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying TreatmentsMar 03
Alterity Therapeutics Presents Promising Impact of Ath434 on Orthostatic Hypotension and Disease Progression in Msa At the 36Th International Symposium on the Autonomic Nervous SystemNov 11
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial At the 2025 International Congress of Parkinson's Disease and Movement DisordersOct 10
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement DisordersOct 03
Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.Sep 08
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System AtrophyJul 29
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the BioMUSE Natural History StudyJul 24
Alterity Therapeutics Grants U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System AtrophyMay 06
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA SymposiumApr 28
Alterity Therapeutics Presents Encouraging New Data from Its Ath434 Phase 2 Trial in Multiple System Atrophy At the American Academy of Neurology Annual MeetingApr 10
Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.Apr 07
Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 40.7 million.Feb 11
Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.118724 million.Feb 04
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical EfficacyJan 30
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System AtrophyDec 04
Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International SymposiumNov 12
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434Nov 06
Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.Jul 20+ 1 more update
Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyJul 17
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewMay 09
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative DiseasesApr 30
Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.Feb 16
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewFeb 06
Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.Jan 08
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's DiseaseDec 04
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNov 29
Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Nov 23+ 1 more update
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System AtrophyNov 10
Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer'sAug 24
Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 StudyJul 27
Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System AtrophyMay 11
Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and AustriaFeb 16
Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's DiseaseJan 31
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System AtrophyJan 25
Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System AtrophyJan 09